The Renaming That Changes Everything: PCOS → PMOS and Why It Took 85 Years

PCOS → PMOS and Why It Took 85 Years

By Dr. Herman Weiss, MD, MBA, FACOG | The Metabolic Fix

I remember exactly where I was when I saw it.

The announcement was official. Polycystic Ovarian Syndrome, the name that has defined, and I would argue confined, millions of women for nearly a century, was being reframed as Polyendocrine Metabolic Ovarian Syndrome. PMOS.

I called it. I’ve been calling it for years.

And immediately, immediately, my phone exploded.

First: Take Your Credit. I Mean It.

Before I say anything else, I want to address the wave of posts and “told you so’s” that flooded every medical social media platform within hours of the announcement. The physicians, researchers, dietitians, and yes, even the patients who have been screaming into the void for decades that this was never just about the ovaries, take your credit. You earned it.

Who cares who planted the flag first? What matters is that we are finally, collectively, talking about this the right way. And when the medical establishment moves, even slowly, even grudgingly, in the right direction, we celebrate it. Because our patients deserve that celebration more than anyone.

But then we get back to work. Because the name change is only the beginning.

Why PCOS Was Always the Wrong Name

Here is what I have said in my office, in lectures, on this newsletter, and in peer-reviewed literature. The ovary is not the villain. The ovary is the victim.

For 85 years, we named this condition after one of its most visible but least causative features, polycystic-appearing ovaries, and in doing so, we set in motion an entire generation of clinical misdirection. We sent women to gynecologists when they needed endocrinologists. We focused on the cysts when we should have been tracking insulin. We treated a metabolic inferno with a reproductive garden hose.

The Rotterdam criteria, as useful as they have been, essentially enshrined this confusion into diagnostic gospel. You could meet PCOS criteria with two of three features. Irregular cycles, hyperandrogenism, or polycystic ovaries on ultrasound. Insulin resistance? Metabolic dysfunction? Not even in the criteria. Not required. Not formally assessed.

We built an entire diagnostic architecture on a foundation that missed the point.

What PMOS Actually Means and Why It Matters Clinically

The new framing, Polyendocrine Metabolic Ovarian Syndrome, changes the story in three critical ways:

1. The endocrine axis comes first. We are now explicitly acknowledging that this is a disorder of hormonal dysregulation that spans multiple endocrine systems — not just gonadal function. The HPO axis, the adrenal contribution, thyroid interplay, and critically, the insulin-IGF-1 signaling axis. These are not peripheral features. They are the engine of this disease.

2. Metabolism is structural, not optional. By embedding “metabolic” into the name itself, we can no longer treat insulin resistance as a comorbidity or a coincidence. It is part of the core diagnosis. This is not a footnote. This is the title of the paper.

3. The ovarian manifestation is downstream. The ovaries are responding to a systemic hormonal and metabolic environment that is fundamentally disordered. The cysts, the anovulation, and the androgen excess at the follicular level are outputs. They are the smoke. The fire is metabolic.

This is not semantics. This is a clinical paradigm shift, and it has real consequences for every woman sitting in a waiting room right now with a diagnosis that has confused her for years.

The Texts and Calls Started the Day of the Announcement

I am not exaggerating when I tell you that the morning after the announcement went live, my phone did not stop.

One text in particular has stayed with me. A patient, a woman I’ve been managing for three years, sent me a message that said simply: “Does this mean I wasn’t crazy?”

She wasn’t crazy. She was right. And she had been told, implicitly and sometimes explicitly, that the drugs she needed were “diabetes drugs,” that her metabolic concerns were secondary, that the primary issue was reproductive and manageable with the pill.

She’d had to fight with her pharmacist, genuinely fight, argue, explain that yes, she has a prescription for metformin, and no, she does not have diabetes. Her doctor prescribed it for other reasons. She had to justify a treatment decision made by a board-certified physician to someone who was reading off a drug indication list that hadn’t caught up with the clinical science.

That is what happens when the name is wrong. The name informs the reimbursement. The reimbursement informs the pharmacy. The pharmacy informs the patient. And the patient, standing at the counter, has to defend her own diagnosis.

PMOS fixes this. Not completely. Not overnight. But it starts fixing it.

The Comment That Made Me Furious

One thing I cannot let pass without direct address: I had a patient come in who had been told by another physician, a physician, that perimenopausal women don’t need to worry about PCOS anymore.

I want to sit with that for a moment.

The logic, presumably, is that if PCOS is fundamentally a reproductive disorder, then once the reproductive window is closing, the condition resolves or becomes irrelevant. Out of ovulatory concern, out of mind.

This is not just wrong. This is dangerous.

Because here is what actually happens to women with PCOS, now PMOS, as they move through perimenopause: their metabolic risk accelerates. The hyperinsulinemia doesn’t disappear when estrogen declines; it compounds. The cardiovascular risk profile, already elevated in PCOS, gets an additional push from the hormonal transition. The visceral adiposity that has been building for decades doesn’t stop building. Non-alcoholic fatty liver disease, type 2 diabetes, and hypertension. These are not conditions that respect the menopause boundary.

Telling a woman with PMOS that she can stop worrying about perimenopause is like telling someone with a genetic lipid disorder that their cholesterol stops mattering at retirement. The condition doesn’t end. The risk doesn’t end. The need for monitoring and metabolic management doesn’t end.

PCOS, PMOS, is a lifelong metabolic condition with reproductive manifestations. Not a reproductive condition that occasionally has metabolic features.

What This Means Going Forward

I will be honest with you. Part of me exhaled when the announcement came through. Not because I needed the validation, though I will accept it, but because this is what liberation looks like when you’ve been fighting an upstream current for years.

Other physicians, researchers, and endocrinologists are now doing the heavy lifting to realign the field. The institutional machinery of medicine, the guidelines committees, the board certifications, the CME modules, and the pharmacy databases will slowly, inevitably follow. And that machinery matters, because it is what reaches the patients who will never find a Substack like this one.

But for those of you reading this right now, whether you are a clinician, a researcher, or a woman sitting with a diagnosis that has never fully made sense to you — hear this clearly:

You were not wrong. The name was wrong.

The ovaries didn’t start this. They were just the part we could see on the ultrasound.

Now we have a name that finally tells the truth. And with the right name, we can finally build the right treatment.

Dr. Herman Weiss, MD, MBA, FACOG is a board-certified OB/GYN with 25 years of clinical experience and the CEO and Founder of ProvationLife™, a physician-led women’s metabolic health company. Follow him @hweissmd on LinkedIn, Instagram, and Substack. Listen to The Metabolic Fix wherever you get your podcasts.

If this resonated with you, share it with a woman who has been told her PCOS “isn’t that serious.” It is. And now, finally, the name says so.

P.S. If you want a deeper, step-by-step approach to managing PMOS, you can explore the master class here: PMOS Master Class